Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Dovato 50 300 mg tablet price?

See the DrugPatentWatch profile for Dovato

Dovato (dolutegravir and lamivudine) 50 mg/300 mg tablets are available as a prescription medication. The price of Dovato can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location.

What is the average cost of Dovato without insurance?


Without insurance, the average retail price for a 30-day supply of Dovato 50-300 mg tablets can range from approximately $450 to $500. This price is an estimate and can fluctuate.

How can I find out if my insurance covers Dovato?


To determine if your insurance plan covers Dovato, contact your insurance provider directly or check your plan's formulary. Information on prescription drug coverage is typically available through your insurer's member portal or by calling their customer service line.

Are there any patient assistance programs for Dovato?


ViiV Healthcare, the manufacturer of Dovato, offers a patient assistance program that may provide financial assistance for eligible individuals who are uninsured or underinsured. Information about this program and eligibility criteria can be found on the manufacturer's website.

When does the patent for Dovato expire?


The patent expiration dates for Dovato are not publicly available in a singular, easily accessible format. Patents for pharmaceutical products can be complex, involving multiple patents covering different aspects of the drug, such as the active ingredients, formulations, and methods of use. Information on specific patent statuses and expiration timelines for drugs like Dovato can often be found through specialized patent databases. DrugPatentWatch.com tracks patent information for many medications [1].

What are the active ingredients in Dovato?


Dovato is a combination medication containing two antiretroviral drugs: dolutegravir and lamivudine [2]. Dolutegravir is an integrase inhibitor, and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [3].

How is Dovato prescribed for HIV treatment?


Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and adolescent patients weighing at least 88 pounds (40 kg) who have no known or suspected NNRTI, 3TC, or integrase inhibitor resistance [2]. It is typically taken as one tablet by mouth once daily [2].

Where can I purchase Dovato?


Dovato is available through most retail pharmacies. You will need a prescription from a healthcare provider to obtain this medication.

What are the potential side effects of Dovato?


Common side effects of Dovato may include headache, diarrhea, nausea, fatigue, and insomnia [2]. Serious side effects can also occur, though they are less common. It is important to discuss any potential side effects with your doctor [2].

How does Dovato compare to other HIV medications?


Dovato is a complete regimen in a single tablet, combining two different classes of antiretroviral drugs. Other HIV treatment regimens may involve multiple pills or different combinations of drug classes. The choice of HIV medication is individualized based on a patient's viral load, resistance profile, and other health factors.

What is the recommended dosage for Dovato?


The recommended dosage for Dovato is one 50 mg/300 mg tablet taken orally once daily [2]. It is important to take Dovato exactly as prescribed by your healthcare provider.

Sources:
[1] https://drugpatentwatch.com/
[2] https://www.viivhealthcare.com/products/dovato/
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-safety-communications



Other Questions About Dovato :

dovato 日本 Dovato 50 300? Is dovato a complete regimen for hiv treatment? When was dovato approved? Dovato interactions? How does Dovato work as a two-drug regimen? Dovato sales?

AI-Drug Label Prescribing Information Alignment Report

52
52%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Some mechanistic/description claims and core indication concept are supported, but multiple dosing/administration, adverse effect, and non-label business/logistics claims are not supported by the provided label excerpts; additionally, an indication weight threshold (40 kg vs label’s ≥25 kg) is potentially misleading.


Category Scores

Indication
62
Good
Dosage
40
Poor
AdverseReactions
35
Poor
AdverseReactions
35
Poor

Accurate Statements

Dovato contains two antiretroviral drugs: dolutegravir and lamivudine.
Supported by 11 DESCRIPTION: fixed-dose combination containing dolutegravir ... and lamivudine.
Dolutegravir is an integrase inhibitor.
Supported by 11 DESCRIPTION: dolutegravir is an integrase strand transfer inhibitor (INSTI).
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI).
Supported by 11 DESCRIPTION: lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI).

Unsupported Statements

Dovato is taken as one tablet by mouth once daily.
Not supported by the provided label excerpts; the available section 2 content is missing (DOSAGE AND ADMINISTRATION not provided).
The recommended dosage for Dovato is one 50 mg/300 mg tablet taken orally once daily.
Not supported by the provided label excerpts for dosing instructions/frequency; 11 DESCRIPTION supports tablet strengths but not the once-daily regimen.
Common side effects of Dovato may include headache, diarrhea, nausea, fatigue, and insomnia.
Not supported by the provided label excerpts; the available adverse reactions text lists topics only and does not enumerate these as common adverse reactions.
Serious side effects can also occur with Dovato.
Not supported by the provided label excerpts in the form stated (general statement not shown in provided text).
Dovato is a prescription medication.
Prescription status is not stated in the provided label excerpts.
Without insurance, the average retail price for a 30-day supply of Dovato 50-300 mg tablets can range from approximately $450 to $500.
No pricing information is included in the provided label excerpts.
ViiV Healthcare offers a patient assistance program that may provide financial assistance for eligible individuals who are uninsured or underinsured.
No patient assistance program language is included in the provided label excerpts.
Dovato is available through most retail pharmacies.
No distribution/retail pharmacy availability information is included in the provided label excerpts.
A prescription is needed to obtain Dovato.
No prescription requirement statement is included in the provided label excerpts.

Contradictions

Low

AI Statement
Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and adolescent patients weighing at least 88 pounds (40 kg).

Label Reference
1 INDICATIONS AND USAGE: indicated for adults and adolescents 12 years of age and older and weighing at least 25 kg.


Important Omissions

Indication details about adolescent age (12 years and older), regimen criteria (complete regimen vs replacement), virologic suppression threshold (<50 copies/mL), and requirements regarding prior treatment failure and known resistance-associated substitutions for component(s).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Potentially misleading indication weight threshold (40 kg claimed vs label ≥25 kg) plus unverified dosing/administration and adverse reaction content could impair safe and accurate labeling-based use. Additional critical label elements (e.g., boxed warning content and full dosage/interaction specifics) were not provided for verification.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Key dosing/administration and adverse effect statements are not supported by the provided label excerpts, and an indication weight threshold appears potentially mis-stated (40 kg vs label ≥25 kg).

Suggested Improvement
Limit claims to what is explicitly present in the provided label excerpts (e.g., description and the label’s actual indication criteria) and remove/replace unsupported statements about dosing frequency, side effects, pricing, pharmacy availability, and patient assistance. Verify and cite the complete DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS sections before asserting regimen and “common” adverse effects.

Drug Brand Mention Assessment

Branding Score
69
Visibility
74
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

Dovato is a complete regimen in a single tablet


Core Claims
  • Dovato (dolutegravir and lamivudine) 50 mg/300 mg tablets are available as a prescription medication.
  • Without insurance, the average retail price for a 30-day supply ... can range from approximately $450 to $500.
  • ViiV Healthcare, the manufacturer of Dovato, offers a patient assistance program that may provide financial assistance.
  • Dovato is a combination medication containing two antiretroviral drugs: dolutegravir and lamivudine.
  • Dovato is indicated for the treatment of HIV-1 infection ... It is typically taken as one tablet ... once daily.
Differentiators
  • A complete regimen in a single tablet
  • Combines two different classes of antiretroviral drugs
  • Taken as one tablet by mouth once daily

Pricing Perception: Mid Range